Commentary describes tension over unapproved retatrutide as Lilly sues sellers
Retatrutide is not approved anywhere, so people who want it must navigate expanded access hurdles or unapproved products sold outside the medical system, according to a new commentary.
A commentary published August 19, 2026 in Medscape says the expanded access process for retatrutide, an experimental weight-loss drug, is "more of an obstacle than it is a bridge" and "potentially pits the doctor against the patient" [1]. The same month, Eli Lilly filed six lawsuits against sellers it says are marketing retatrutide products for human use even though the drug is not approved [2].
Retatrutide is Lilly's triple GLP-1/GIP/glucagon agonist. According to the commentary, it has completed all four core TRIUMPH phase 3 trials plus a diabetes-focused TRANSCEND trial, with up to roughly 28%–30% average body weight loss at the highest doses and improvements in cholesterol, blood pressure, sleep apnea severity and knee osteoarthritis pain [1]. The commentary says its safety profile looks similar to semaglutide and tirzepatide [1]. Retatrutide is not approved by any regulatory agency, and Lilly does not sell it commercially [2]. Lilly is expected to file for FDA approval in the first quarter of 2027 [1].
The commentary, by endocrinologist Caroline Messer, MD, describes an expanded access program that patients must clear in sequence. To be considered at all, a patient must be at least 18, have obesity that has not responded adequately despite already taking the highest approved, tolerable dose of a currently approved obesity medication, have at least two serious or life-threatening obesity-related conditions actively managed by a medical team, and be unable to enroll in a retatrutide trial or a similar investigational drug trial [1].
After that, three separate gates follow. First, Lilly's expanded access office must issue a letter of authorization referencing the drug's investigational new drug application; the commentary calls this the longest and least predictable step, saying it can take weeks or months with no guaranteed timeline [1]. Second, the physician files FDA Form 3926. Third, an institutional review board reviews the request; these reviews are designed to be expedited and typically turn around in 24–48 hours, according to the commentary [1]. Each step runs on its own timeline, and a "no" or silence from any one of them stops the process. The commentary says there is no built-in appeals process, no single point of accountability and no way to run the steps in parallel, and that the process can stretch to the better part of a year before a dose is authorized [1].
The commentary states that Lilly has not publicly disclosed how many requests it intends to approve, how long treatment would be permitted to continue if approved, or who is expected to cover the cost of the drug and the monitoring it requires [1].
The six lawsuits, filed in California and Texas on August 12, name Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide [2]. Lilly alleges the defendants marketed unapproved retatrutide products for weight loss and other human uses, including products labeled "research use only" [2]. Analysts project retatrutide revenue of roughly $5.3 billion by 2030, according to the same report [2]. No rulings in those cases have been reported.
Why it matters for patients
There is no legal prescription path to retatrutide in the United States. The drug is available only through Lilly-sponsored trials or the narrow expanded access program described in the commentary [1]. Meeting every eligibility criterion does not guarantee access, because each of the three approval steps can stop the request, and the first step has no published timeline [1]. Cost and duration of treatment are also unresolved, because Lilly has not disclosed those terms [1].
The products named in the lawsuits are a separate issue. Lilly's filings allege unapproved retatrutide products were sold or promoted for human use, including items labeled for research only, which have not gone through regulatory review for safety, purity or dosing [2]. The allegations have not been resolved in court.
What happens next
Lilly is expected to file for FDA approval of retatrutide in the first quarter of 2027 [1]. The six lawsuits were filed on August 12, 2026, and no decisions have been reported [2]. For patients pursuing expanded access now, the commentary says the Lilly authorization step can take weeks or months, while the IRB step typically takes 24–48 hours once it is reached [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.